The goal is to have a capacity of over 1.2 million liters per year.
Wuhan Institute of Biological Products obtained exclusive access to ProMetic Life Sciences’ Plasma Protein Purification System (PPPS) for the Chinese market.
Full-scale commercial manufacturing will initially take place at WIBP and could be later implemented by an affiliated firm within China National Biotec Group, WIBP’s parent company. The goal is to achieve a minimum capacity greater than 1.2 million liters of plasma per year.
ProMetic will assist WIBP in implementing a product development program begining immediately. This includes training, technology transfer, and scale-up as well as readiness of the clinical manufacturing facility. WIBP will take the lead in conducting the clinical trials to obtain required regulatory approval by the Chinese State Food and Drug Administration (SFDA).
